Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 31;10:2545. doi: 10.3389/fimmu.2019.02545

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Cabanas, Muraki, Staines and Marshall-Gradisnik.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Modulation of PregS- evoked currents with Ononetin. Data were obtained under whole-cell patch clamp conditions. (A) A representative time-series of current amplitude at +100 mV and −100 mV showing the effect of 10 μM ononetin (gray) on ionic currents in the presence of 100 μM PregS in IL-2 stimulated NK cells from HC. (B) I–V before and after the first application of ononetin in the presence of PregS in a cell as shown in (A). (C) I–V before and after the second application of ononetin in the presence of PregS in a cell as shown in (A). (D) A representative time-series of current amplitude at +100 mV and −100 mV showing the effect of 10 μM ononetin (gray) on ionic currents in the presence of 100 μM PregS in IL-2 stimulated NK cells ME/CFS patients. (E) I–V before and after the first application of ononetin in the presence of PregS in a cell as shown in (D). (F) I–V before and after the second application of ononetin in the presence of PregS in a cell as shown in (D). (G,H) Scatter plots representing change of each current amplitude before and after the first application of ononetin in presence of PregS in all NK cells from HC and ME/CFS patients. Each cell represented as red lines had reduction in currents by ononetin. (I,J) Scatter plots representing change of each current amplitude before and after the second application of ononetin in presence of PregS in all NK cells from HC and ME/CFS patients. Each cell represented as red lines had reduction in currents by ononetin. (K) Table summarizing data for sensitive and insensitive cells to the first application of 10 μM ononetin in presence of PregS in HC (N = 8; n = 31) compared to ME/CFS patients (N = 8; n = 27). (L) Table summarizing data for sensitive and insensitive cells to the second application of 10 μM ononetin in presence of PregS in HC (N = 8; n = 29) compared to ME/CFS patients (N = 8; n = 24). Data are analyzed with Fisher's exact test. ME/CFS, myalgic encephalomyelitis/chronic fatigue syndrome; HC, healthy controls; NK, natural killer; PregS, Pregnenolone sulfate; TRPM3, Transient Receptor Potential Melastatin 3.